No effect on QT intervals of mipomersen, a 2′-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects

Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects

(2015) Laura Rabinovich-Guilatt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Incorporating exposure-response modeling into the assessment of QTc interval: A potential alternative to the thorough QT study

(2015) DM Bloomfield   CLINICAL PHARMACOLOGY & THERAPEUTICS

Results From the IQ-CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase

(2015) B Darpo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14

(2015) Borje Darpo et al.   DRUG SAFETY

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

(2013) Raul D. Santos et al.   EUROPEAN HEART JOURNAL

Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies

(2013) Tae-Won Kim et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

(2011) Fatima Akdim et al.   EUROPEAN HEART JOURNAL

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

(2010) Fatima Akdim et al.   AMERICAN JOURNAL OF CARDIOLOGY

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

(2010) Fatima Akdim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET